Publications
Found 4 results
Filters: Author is C. Ronpirin [Clear All Filters]
“Dithranol downregulates expression of Id1 mRNA in human keratinocytes in vitro”, vol. 11, pp. 3290-3297, 2012.
,
Afifi T, de GG, Huang C and Zhou Y (2005). Topical therapies for psoriasis: evidence-based review. Can. Fam. Physician 51: 519-525.
PMid:15856971 PMCid:1472956
Benezra R, Davis RL, Lockshon D, Turner DL, et al. (1990). The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell 61: 49-59.
http://dx.doi.org/10.1016/0092-8674(90)90214-Y
Bjorntorp E, Parsa R, Thornemo M, Wennberg AM, et al. (2003). The helix-loop-helix transcription factor Id1 is highly expressed in psoriatic involved skin. Acta Derm. Venereol. 83: 403-409.
http://dx.doi.org/10.1080/00015550310015806
PMid:14690332
Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, et al. (1988). Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J. Cell. Biol. 106: 761-771.
http://dx.doi.org/10.1083/jcb.106.3.761
PMid:2450098
Bradford MM (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254.
http://dx.doi.org/10.1016/0003-2697(76)90527-3
Cheng YJ, Tsai JW, Hsieh KC, Yang YC, et al. (2011). Id1 promotes lung cancer cell proliferation and tumor growth through Akt-related pathway. Cancer Lett. 307: 191-199.
http://dx.doi.org/10.1016/j.canlet.2011.04.003
PMid:21536374
Farkas A, Kemeny L, Szony BJ, Bata-Csorgo Z, et al. (2001). Dithranol upregulates IL-10 receptors on the cultured human keratinocyte cell line HaCaT. Inflamm. Res. 50: 44-49.
http://dx.doi.org/10.1007/s000110050723
PMid:11235021
George SE, Anderson RJ, Cunningham A, Donaldson M, et al. (2010). Evaluation of a range of anti-proliferative assays for the preclinical screening of anti-psoriatic drugs: a comparison of colorimetric and fluorimetric assays with the thymidine incorporation assay. Assay Drug Dev. Technol. 8: 389-400.
http://dx.doi.org/10.1089/adt.2009.0224
PMid:20482335
Gry M, Rimini R, Stromberg S, Asplund A, et al. (2009). Correlations between RNA and protein expression profiles in 23 human cell lines. BMC Genomics 10: 365.
http://dx.doi.org/10.1186/1471-2164-10-365
PMid:19660143 PMCid:2728742
Guo Y, Xiao P, Lei S, Deng F, et al. (2008). How is mRNA expression predictive for protein expression? A correlation study on human circulating monocytes. Acta Biochim. Biophys. Sin. 40: 426-436.
http://dx.doi.org/10.1111/j.1745-7270.2008.00418.x
Hamajima Y, Komori M, Preciado DA, Choo DI, et al. (2010). The role of inhibitor of DNA-binding (Id1) in hyperproliferation of keratinocytes: the pathological basis for middle ear cholesteatoma from chronic otitis media. Cell Prolif. 43: 457-463.
http://dx.doi.org/10.1111/j.1365-2184.2010.00695.x
PMid:20887552 PMCid:2950310
Jacobson CC, Kumar S and Kimball AB (2011). Latitude and psoriasis prevalence. J. Am. Acad. Dermatol. 65: 870-873.
http://dx.doi.org/10.1016/j.jaad.2009.05.047
PMid:21920244
Kamili QU and Menter A (2009). Topical treatment of psoriasis. Curr. Probl. Dermatol. 38: 37-58.
http://dx.doi.org/10.1159/000232303
PMid:19710549
Lichtinghagen R, Musholt PB, Lein M, Römer A, et al. (2002). Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue. Eur. Urol. 42: 398-406.
http://dx.doi.org/10.1016/S0302-2838(02)00324-X
Ling MT, Lau TC, Zhou C, Chua CW, et al. (2005). Overexpression of Id-1 in prostate cancer cells promotes angiogenesis through the activation of vascular endothelial growth factor (VEGF). Carcinogenesis 26: 1668-1676.
http://dx.doi.org/10.1093/carcin/bgi128
PMid:15905202
Ling YX, Tao J, Fang SF, Hui Z, et al. (2011). Downregulation of Id1 by small interfering RNA in prostate cancer PC3 cells in vivo and in vitro. Eur. J. Cancer Prev. 20: 9-17.
http://dx.doi.org/10.1097/CEJ.0b013e32833ebaa0
PMid:20881502
Lister J, Forrester WC and Baron MH (1995). Inhibition of an erythroid differentiation switch by the helix-loop-helix protein Id1. J. Biol. Chem. 270: 17939-17946.
http://dx.doi.org/10.1074/jbc.270.30.17939
PMid:7629100
Lyden D, Young AZ, Zagzag D, Yan W, et al. (1999). Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature 401: 670-677.
http://dx.doi.org/10.1038/44334
PMid:10537105
Mark EB, Jonsson M, Asp J, Wennberg AM, et al. (2006). Expression of genes involved in the regulation of p16 in psoriatic involved skin. Arch. Dermatol. Res. 297: 459-467.
http://dx.doi.org/10.1007/s00403-006-0649-1
PMid:16552541
Massari ME and Murre C (2000). Helix-loop-helix proteins: regulators of transcription in eucaryotic organisms. Mol. Cell Biol. 20: 429-440.
http://dx.doi.org/10.1128/MCB.20.2.429-440.2000
PMid:10611221 PMCid:85097
McAllister SD, Christian RT, Horowitz MP, Garcia A, et al. (2007). Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Mol. Cancer Ther. 6: 2921-2927.
http://dx.doi.org/10.1158/1535-7163.MCT-07-0371
PMid:18025276
McAllister SD, Murase R, Christian RT, Lau D, et al. (2011). Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Res. Treat. 129: 37-47.
http://dx.doi.org/10.1007/s10549-010-1177-4
PMid:20859676 PMCid:3410650
Ouyang XS, Wang X, Lee DT, Tsao SW, et al. (2002). Over expression of ID-1 in prostate cancer. J. Urol. 167: 2598-2602.
http://dx.doi.org/10.1016/S0022-5347(05)65044-6
Pavithran K (2001). Psoriasis: topical treatment. Indian J. Dermatol. Venereol. Leprol. 67: 85.
PMid:17664716
Ristow HJ (1996). Studies on stimulation of DNA synthesis with epidermal growth factor and insulin-like growth factor-I in cultured human keratinocytes. Growth Regul. 6: 96-109.
PMid:8781986
Ronpirin C and Tencomnao T (2012). Effects of the antipsoriatic drug dithranol on E2A and caspase-9 gene expression in vitro. Genet. Mol. Res. 11: 412-420.
http://dx.doi.org/10.4238/2012.February.17.3
PMid:22370944
Ronpirin C, Achariyakul M, Tencomnao T, Wongpiyabovorn J, et al. (2010). Up-regulation of Id1 in peripheral blood of psoriatic patients. Genet. Mol. Res. 9: 2239-2247.
http://dx.doi.org/10.4238/vol9-4gmr963
PMid:21086260
Saelee C, Thongrakard V and Tencomnao T (2011). Effects of Thai medicinal herb extracts with anti-psoriatic activity on the expression on NF-kappaB signaling biomarkers in HaCaT keratinocytes. Molecules 16: 3908-3932.
http://dx.doi.org/10.3390/molecules16053908
PMid:21555979
Sakurai D, Yamaguchi A, Tsuchiya N, Yamamoto K, et al. (2001). Expression of ID family genes in the synovia from patients with rheumatoid arthritis. Biochem. Biophys. Res. Commun. 284: 436-442.
http://dx.doi.org/10.1006/bbrc.2001.4974
PMid:11394898
Schindl M, Schoppmann SF, Strobel T, Heinzl H, et al. (2003). Level of Id-1 protein expression correlates with poor differentiation, enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors. Clin. Cancer Res. 9: 779-785.
PMid:12576450
Schoppmann SF, Schindl M, Bayer G, Aumayr K, et al. (2003). Overexpression of Id-1 is associated with poor clinical outcome in node negative breast cancer. Int. J. Cancer 104: 677-682.
http://dx.doi.org/10.1002/ijc.11009
PMid:12640673
Tencomnao T, Ronpirin C, Prasansuklab A and Poovorawan Y (2009). Decreased EGFR mRNA expression in response to antipsoriatic drug dithranol in vitro. Afr. J. Biotechnol. 8: 3141-3146.
Villano CM and White LA (2006). Expression of the helix-loop-helix protein inhibitor of DNA binding-1 (ID-1) is activated by all-trans retinoic acid in normal human keratinocytes. Toxicol. Appl. Pharmacol. 214: 219-229.
http://dx.doi.org/10.1016/j.taap.2005.12.015
PMid:16494909
Wong YC, Wang X and Ling MT (2004). Id-1 expression and cell survival. Apoptosis 9: 279-289.
http://dx.doi.org/10.1023/B:APPT.0000025804.25396.79
PMid:15258459
“Effects of the antipsoriatic drug dithranol on E2A and caspase-9 gene expression in vitro”, vol. 11, pp. 412-420, 2012.
, Allen D, Winters E, Kenna PF, Humphries P, et al. (2008). Reference gene selection for real-time rtPCR in human epidermal keratinocytes. J. Dermatol. Sci. 49: 217-225.
http://dx.doi.org/10.1016/j.jdermsci.2007.10.001
PMid:18061409
Bjorntorp E, Parsa R, Thornemo M, Wennberg AM, et al. (2003). The helix-loop-helix transcription factor Id1 is highly expressed in psoriatic involved skin. Acta Derm. Venereol. 83: 403-409.
http://dx.doi.org/10.1080/00015550310015806
PMid:14690332
Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, et al. (1988). Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J. Cell Biol. 106: 761-771.
http://dx.doi.org/10.1083/jcb.106.3.761
PMid:2450098
Bradford MM (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254.
http://dx.doi.org/10.1016/0003-2697(76)90527-3
Engel I and Murre C (2001). The function of E- and Id proteins in lymphocyte development. Nat. Rev. Immunol. 1: 193- 199.
http://dx.doi.org/10.1038/35105060
PMid:11905828
Farkas A, Kemeny L, Szony BJ, Bata-Csorgo Z, et al. (2001). Dithranol upregulates IL-10 receptors on the cultured human keratinocyte cell line HaCaT. Inflamm. Res. 50: 44-49.
http://dx.doi.org/10.1007/s000110050723
PMid:11235021
Henseleit U, Rosenbach T and Kolde G (1996). Induction of apoptosis in human HaCaT keratinocytes. Arch. Dermatol. Res. 288: 676-683.
http://dx.doi.org/10.1007/BF02505277
PMid:8931870
Kee BL (2009). E and ID proteins branch out. Nat. Rev. Immunol. 9: 175-184.
http://dx.doi.org/10.1038/nri2507
PMid:19240756
Kemeny L, Ruzicka T and Braun-Falco O (1990). Dithranol: a review of the mechanism of action in the treatment of psoriasis vulgaris. Skin Pharmacol. 3: 1-20.
http://dx.doi.org/10.1159/000210836
Kuida K (2000). Caspase-9. Int. J. Biochem. Cell Biol. 32: 121-124.
http://dx.doi.org/10.1016/S1357-2725(99)00024-2
Langlands K, Down GA and Kealey T (2000). Id proteins are dynamically expressed in normal epidermis and dysregulated in squamous cell carcinoma. Cancer Res. 60: 5929-5933.
PMid:11085505
Lowes MA, Bowcock AM and Krueger JG (2007). Pathogenesis and therapy of psoriasis. Nature 445: 866-873.
http://dx.doi.org/10.1038/nature05663
PMid:17314973
Mark EB, Jonsson M, Asp J, Wennberg AM, et al. (2006). Expression of genes involved in the regulation of p16 in psoriatic involved skin. Arch. Dermatol. Res. 297: 459-467.
http://dx.doi.org/10.1007/s00403-006-0649-1
PMid:16552541
Olson EN and Klein WH (1994). bHLH factors in muscle development: dead lines and commitments, what to leave in and what to leave out. Genes Dev. 8: 1-8.
http://dx.doi.org/10.1101/gad.8.1.1
Oztas P, Lortlar N, Oztas MO, Omeroglu S, et al. (2006). Caspase 9 is decreased in psoriatic epidermis. Acta Histochem. 108: 497-499.
http://dx.doi.org/10.1016/j.acthis.2006.09.002
PMid:17034836
Pavithran K (2001). Psoriasis: topical treatment. Indian J. Dermatol. Venereol. Leprol. 67: 85.
PMid:17664716
Perk J, Iavarone A and Benezra R (2005). Id family of helix-loop-helix proteins in cancer. Nat. Rev. Cancer 5: 603-614.
http://dx.doi.org/10.1038/nrc1673
PMid:16034366
Raymond AA, Mechin MC, Nachat R, Toulza E, et al. (2007). Nine procaspases are expressed in normal human epidermis, but only caspase-14 is fully processed. Br. J. Dermatol. 156: 420-427.
http://dx.doi.org/10.1111/j.1365-2133.2006.07656.x
PMid:17300228
Ronpirin C, Achariyakul M, Tencomnao T, Wongpiyabovorn J, et al. (2010). Up-regulation of Id1 in peripheral blood of psoriatic patients. Genet. Mol. Res. 9: 2239-2247.
http://dx.doi.org/10.4238/vol9-4gmr963
PMid:21086260
Schon MP and Boehncke WH (2005). Psoriasis. N. Engl. J. Med. 352: 1899-1912.
http://dx.doi.org/10.1056/NEJMra041320
PMid:15872205
Tencomnao T, Ronpirin C, Prasansuklab A and Poovorawan Y (2009). Decreased EGFR mRNA expression in response to antipsoriatic drug dithranol in vitro. Afr. J. Biotechnol. 8: 3141-3146.
Yamamoto T and Nishioka K (2003). Alteration of the expression of Bcl-2, Bcl-x, Bax, Fas, and Fas ligand in the involved skin of psoriasis vulgaris following topical anthralin therapy. Skin Pharmacol. Appl. Skin Physiol. 16: 50-58.
http://dx.doi.org/10.1159/000068289
Yan W, Young AZ, Soares VC, Kelley R, et al. (1997). High incidence of T-cell tumors in E2A-null mice and E2A/Id1 double-knockout mice. Mol. Cell Biol. 17: 7317-7327.
PMid:9372963 PMCid:232588
“Association between the -1438A/G polymorphism of the serotonin 2A receptor gene and late-onset psoriasis in a Thai population”, vol. 9, pp. 208-214, 2010.
, Azmitia EC (2001). Modern views on an ancient chemical: serotonin effects on cell proliferation, maturation, and apoptosis. Brain Res. Bull. 56: 413-424.
http://dx.doi.org/10.1016/S0361-9230(01)00614-1
Barth JH and Baker H (1986). Generalized pustular psoriasis precipitated by trazodone in the treatment of depression. Br. J. Dermatol. 115: 629-630.
http://dx.doi.org/10.1111/j.1365-2133.1986.tb05776.x
Bray NJ, Buckland PR, Hall H, Owen MJ, et al. (2004). The serotonin-2A receptor gene locus does not contain common polymorphism affecting mRNA levels in adult brain. Mol. Psychiatry 9: 109-114.
http://dx.doi.org/10.1038/sj.mp.4001366
PMid:14699448
Collier DA, Arranz MJ, Li T, Mupita D, et al. (1997). Association between 5-HT2A gene promoter polymorphism and anorexia nervosa. Lancet 350: 412.
http://dx.doi.org/10.1016/S0140-6736(05)64135-9
Conn PJ, Sanders-Bush E, Hoffman BJ and Hartig PR (1986). A unique serotonin receptor in choroid plexus is linked to phosphatidylinositol turnover. Proc. Natl. Acad. Sci. U. S. A. 83: 4086-4088.
http://dx.doi.org/10.1073/pnas.83.11.4086
Griffiths CE and Richards HL (2001). Psychological influences in psoriasis. Clin. Exp. Dermatol. 26: 338-342.
http://dx.doi.org/10.1046/j.1365-2230.2001.00834.x
PMid:11422186
Guillet-Deniau I, Burnol AF and Girard J (1997). Identification and localization of a skeletal muscle serotonin 5-HT2A receptor coupled to the Jak/STAT pathway. J. Biol. Chem. 272: 14825-14829.
http://dx.doi.org/10.1074/jbc.272.23.14825
PMid:9169451
Hoyer D, Hannon JP and Martin GR (2002). Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav. 71: 533-554.
http://dx.doi.org/10.1016/S0091-3057(01)00746-8
Huang J, Li G, Xiang J, Yin D, et al. (2004). Immunohistochemical study of serotonin in lesions of psoriasis. Int. J. Dermatol. 43: 408-411.
http://dx.doi.org/10.1111/j.1365-4632.2004.02195.x
Kling A, Seddighzadeh M, Arlestig L, Alfredsson L, et al. (2008). Genetic variations in the serotonin 5-HT2A receptor gene (HTR2A) are associated with rheumatoid arthritis. Ann. Rheum. Dis. 67: 1111-1115.
http://dx.doi.org/10.1136/ard.2007.074948
PMid:18006541
León-Ponte M, Ahern GP and O'Connell PJ (2007). Serotonin provides an accessory signal to enhance T-cell activation by signaling through the 5-HT7 receptor. Blood 109: 3139-3146.
http://dx.doi.org/10.1182/blood-2006-10-052787
Locala JA (2009). Current concepts in psychodermatology. Curr. Psychiatry Rep. 11: 211-218.
http://dx.doi.org/10.1007/s11920-009-0033-x
Lowes MA, Bowcock AM and Krueger JG (2007). Pathogenesis and therapy of psoriasis. Nature 445: 866-873.
http://dx.doi.org/10.1038/nature05663
PMid:17314973
Miller SA, Dykes DD and Polesky HF (1988). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16: 1215.
http://dx.doi.org/10.1093/nar/16.3.1215
Mössner R, Stiens G, König IR, Schmidt D, et al. (2009). Analysis of a functional serotonin transporter promoter polymorphism in psoriasis vulgaris. Arch. Dermatol. Res. 301: 443-447.
http://dx.doi.org/10.1007/s00403-008-0909-3
PMid:18979110
Myers RL, Airey DC, Manier DH, Shelton RC, et al. (2007). Polymorphisms in the regulatory region of the human serotonin 5-HT2A receptor gene (HTR2A) influence gene expression. Biol. Psychiatry 61: 167-173.
http://dx.doi.org/10.1016/j.biopsych.2005.12.018
Nedoszytko B, Szczerkowska-Dobosz A, Zablotna M, Glen J, et al. (2007). Associations of promoter region polymorphisms in the tumour necrosis factor-alpha gene and early-onset psoriasis vulgaris in a northern Polish population. Br. J. Dermatol. 157: 165-167.
http://dx.doi.org/10.1111/j.1365-2133.2007.07993.x
Nordlind K, Thorslund K, Lonne-Rahm S, Mohabbati S, et al. (2006). Expression of serotonergic receptors in psoriatic skin. Arch. Dermatol. Res. 298: 99-106.
http://dx.doi.org/10.1007/s00403-006-0652-6
O'Sullivan RL, Lipper G and Lerner EA (1998). The neuro-immuno-cutaneous-endocrine network: relationship of mind and skin. Arch. Dermatol. 134: 1431-1435.
http://dx.doi.org/10.1001/archderm.134.11.1431
Ohara K, Nagai M, Tani K, Tsukamoto T, et al. (1999). Schizophrenia and the serotonin-2A receptor promoter polymorphism. Psychiatry Res. 85: 221-224.
http://dx.doi.org/10.1016/S0165-1781(99)00002-5
Ono H, Shirakawa O, Nishiguchi N, Nishimura A, et al. (2001). Serotonin 2A receptor gene polymorphism is not associated with completed suicide. J. Psychiatr. Res. 35: 173-176.
http://dx.doi.org/10.1016/S0022-3956(01)00015-2
Osborne SF, Stafford L and Orr KG (2002). Paroxetine-associated psoriasis. Am. J. Psychiatry 159: 2113.
http://dx.doi.org/10.1176/appi.ajp.159.12.2113
PMid:12450972
Parsons MJ, D'Souza UM, Arranz MJ, Kerwin RW, et al. (2004). The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity. Biol. Psychiatry 56: 406-410.
http://dx.doi.org/10.1016/j.biopsych.2004.06.020
Peters BP, Weissman FG and Gill MA (2000). Pathophysiology and treatment of psoriasis. Am. J. Health Syst. Pharm. 57: 645-659.
Reich K, Mossner R, Konig IR, Westphal G, et al. (2002). Promoter polymorphisms of the genes encoding tumor necrosis factor-alpha and interleukin-1beta are associated with different subtypes of psoriasis characterized by early and late disease onset. J. Invest. Dermatol. 118: 155-163.
http://dx.doi.org/10.1046/j.0022-202x.2001.01642.x
Schön MP and Boehncke WH (2005). Psoriasis. N. Engl. J. Med. 352: 1899-1912.
http://dx.doi.org/10.1056/NEJMra041320
Serretti A, Drago A and De Ronchi D (2007). HTR2A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. Curr. Med. Chem. 14: 2053-2069.
http://dx.doi.org/10.2174/092986707781368450
Smith AK, Dimulescu I, Falkenberg VR, Narasimhan S, et al. (2008). Genetic evaluation of the serotonergic system in chronic fatigue syndrome. Psychoneuroendocrinology 33: 188-197.
http://dx.doi.org/10.1016/j.psyneuen.2007.11.001
Sparkes RS, Lan N, Klisak I, Mohandas T, et al. (1991). Assignment of a serotonin 5HT-2 receptor gene (HTR2) to human chromosome 13q14-q21 and mouse chromosome 14. Genomics 9: 461-465.
http://dx.doi.org/10.1016/0888-7543(91)90411-7
Stefulj J, Jernej B, Cicin-Sain L, Rinner I, et al. (2000). mRNA expression of serotonin receptors in cells of the immune tissues of the rat. Brain Behav. Immun. 14: 219-224.
http://dx.doi.org/10.1006/brbi.1999.0579
Tan Pei Lin L and Kwek SK (2009). Onset of psoriasis during therapy with fluoxetine. Gen. Hosp. Psychiatry (in press) DOI: 10.1016/j.genhosppsych.2009.08.008.
http://dx.doi.org/10.1016/j.genhosppsych.2009.08.008
Tencomnao T and Boonmalert R (2009). Misgenotyping of dopamine receptor D1 gene -48A/G polymorphism. Am. J. Med. Genet. B Neuropsychiatr. Genet. 150B: 447-449.
http://dx.doi.org/10.1002/ajmg.b.30814
Tencomnao T, Ketboonlue K, Wongpiyabavorn J, Ronpirin C, et al. (2007). Analysis of autoantibodies to serotonin and serotonin levels in psoriasis. Chin. Med. J. 120: 146.
Turecki G, Briere R, Dewar K, Antonetti T, et al. (1999). Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide. Am. J. Psychiatry 156: 1456-1458.
Warren JT Jr, Peacock ML, Rodriguez LC and Fink JK (1993). An MspI polymorphism in the hyman serotonin receptor gene (HTR2): detection by DGGE and RFLP analysis. Hum. Mol. Genet. 2: 338.
http://dx.doi.org/10.1093/hmg/2.3.338
Wongpiyabovorn J, Yooyongsatit S, Ruchusatsawat K, Avihingsanon Y, et al. (2008a). Association of the CTG (-2578/-460/+405) haplotype within the vascular endothelial growth factor gene with early-onset psoriasis. Tissue Antigens 72: 458-463.
http://dx.doi.org/10.1111/j.1399-0039.2008.01134.x
Wongpiyabovorn J, Hirankarn N, Ruchusatsawat K, Yooyongsatit S, et al. (2008b). Association of the interleukin-10 distal promoter (-2763A/C) polymorphism with late-onset psoriasis. Clin. Exp. Dermatol. 33: 186-189.
http://dx.doi.org/10.1111/j.1365-2230.2007.02628.x
Wu J, Chen F, Zhang X, Li Y, et al. (2009). Association of MIF promoter polymorphisms with psoriasis in a Han population in northeastern China. J. Dermatol. Sci. 53: 212-215.
http://dx.doi.org/10.1016/j.jdermsci.2008.11.002
Ying S, Liu XM, Sun YM and Pan SH (2009). Genetic polymorphism c.1438A>G of the 5-HT(2A) receptor is associated with abdominal obesity in Chinese Northern Han population. Mol. Biol. Rep. 36: 91-95.
http://dx.doi.org/10.1007/s11033-007-9155-6
Zhang J, Shen Y, He G, Li X, et al. (2008). Lack of association between three serotonin genes and suicidal behavior in Chinese psychiatric patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 32: 467-471.
http://dx.doi.org/10.1016/j.pnpbp.2007.09.019
“Up-regulation of Id1 in peripheral blood of psoriatic patients”, vol. 9, pp. 2239-2247, 2010.
, Abrams JR, Kelley SL, Hayes E, Kikuchi T, et al. (2000). Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J. Exp. Med. 192: 681-694.
http://dx.doi.org/10.1084/jem.192.5.681
PMid:10974034 PMCid:2193278
Ackerman AB (1978). Psoriasis. In: Histologic Diagnosis of Inflammatory Skin Diseases (Ackerman AB, ed.). Lea and Febiger, Philadelphia, 251-256.
Austin LM, Ozawa M, Kikuchi T, Walters IB, et al. (1999). The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J. Invest. Dermatol. 113: 752-759.
http://dx.doi.org/10.1046/j.1523-1747.1999.00749.x
PMid:10571730
Bata-Csorgo Z, Hammerberg C, Voorhees JJ and Cooper KD (1995a). Intralesional T-lymphocyte activation as a mediator of psoriatic epidermal hyperplasia. J. Invest. Dermatol. 105: 89S-94S.
http://dx.doi.org/10.1038/jid.1995.18
PMid:7616005
Bata-Csorgo Z, Hammerberg C, Voorhees JJ and Cooper KD (1995b). Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes. J. Clin. Invest. 95: 317-327.
http://dx.doi.org/10.1172/JCI117659
PMid:7529261 PMCid:295434
Bjorntorp E, Parsa R, Thornemo M, Wennberg AM, et al. (2003). The helix-loop-helix transcription factor Id1 is highly expressed in psoriatic involved skin. Acta Derm. Venereol. 83: 403-409.
http://dx.doi.org/10.1080/00015550310015806
PMid:14690332
Böhm I (2006). Quantification of absolute peripheral white blood cells and their subsets in patients with lupus erythematosus: comparison with other inflammatory diseases with and without autoimmune background. Biomed. Pharmacother. 60: 92-95.
http://dx.doi.org/10.1016/j.biopha.2005.06.007
PMid:16256301
Bonifati C, Carducci M, Cordiali FP, Trento E, et al. (1994). Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients - relationships with disease severity. Clin. Exp. Dermatol. 19: 383-387.
http://dx.doi.org/10.1111/j.1365-2230.1994.tb02687.x
PMid:7955493
Ettehadi P, Greaves MW, Wallach D, Aderka D, et al. (1994). Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin. Exp. Immunol. 96: 146-151.
http://dx.doi.org/10.1111/j.1365-2249.1994.tb06244.x
PMid:8149659 PMCid:1534536
Friedrich M, Krammig S, Henze M, Docke WD, et al. (2000). Flow cytometric characterization of lesional T cells in psoriasis: intracellular cytokine and surface antigen expression indicates an activated, memory/effector type 1 immunophenotype. Arch. Dermatol. Res. 292: 519-521.
http://dx.doi.org/10.1007/s004030000167
PMid:11142774
Gottlieb AB, Lebwohl M, Shirin S, Sherr A, et al. (2000). Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. J. Am. Acad. Dermatol. 43: 595-604.
http://dx.doi.org/10.1067/mjd.2000.107945
PMid:11004613
Gottlieb AB, Masud S, Ramamurthi R, Abdulghani A, et al. (2003). Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J. Am. Acad. Dermatol. 48: 68-75.
http://dx.doi.org/10.1067/mjd.2003.10
PMid:12522373
Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, et al. (1995). Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat. Med. 1: 442-447.
http://dx.doi.org/10.1038/nm0595-442
PMid:7585092
Henseler T (1998). Genetics of psoriasis. Arch. Dermatol. Res. 290: 463-476.
http://dx.doi.org/10.1007/s004030050338
PMid:9808339
Hu LH, Chen FH, Li YR and Wang L (2004). Real-time determination of human telomerase reverse transcriptase mRNA in gastric cancer. World J. Gastroenterol. 10: 3514-3517.
PMid:15526376
Ishiguro A, Spirin KS, Shiohara M, Tobler A, et al. (1996). Id2 expression increases with differentiation of human myeloid cells. Blood 87: 5225-5231.
PMid:8652837
Jeffes EW III, McCullough JL, Pittelkow MR, McCormick A, et al. (1995). Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. J. Invest. Dermatol. 104: 183-188.
http://dx.doi.org/10.1111/1523-1747.ep12612745
PMid:7829873
Ketboonlue K (2007). Detection of Serotonin and Development of Laboratory Technique for Detecting Autoantibodies to Serotonin in the Psoriatic Patients' Blood. Master's thesis, Chulalongkorn University, Bangkok.
Krueger JG, Walters IB, Miyazawa M, Gilleaudeau P, et al. (2000). Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J. Am. Acad. Dermatol. 43: 448-458.
http://dx.doi.org/10.1067/mjd.2000.106515
PMid:10954656
Kupper TS (2003). Immunologic targets in psoriasis. N. Engl. J. Med. 349: 1987-1990.
http://dx.doi.org/10.1056/NEJMp038164
PMid:14627782
Lowes MA, Bowcock AM and Krueger JG (2007). Pathogenesis and therapy of psoriasis. Nature 445: 866-873.
http://dx.doi.org/10.1038/nature05663
PMid:17314973
Mark EB, Jonsson M, Asp J, Wennberg AM, et al. (2006). Expression of genes involved in the regulation of p16 in psoriatic involved skin. Arch. Dermatol. Res. 297: 459-467.
http://dx.doi.org/10.1007/s00403-006-0649-1
PMid:16552541
Marsland AM and Griffiths CE (2002). The macrolide immunosuppressants in dermatology: mechanisms of action. Eur. J. Dermatol. 12: 618-622.
PMid:12459545
Nair RP, Duffin KC, Helms C, Ding J, et al. (2009). Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat. Genet. 41: 199-204.
http://dx.doi.org/10.1038/ng.311
PMid:19169254 PMCid:2745122
Naldi L (2010). Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the ideal method? Is PASI passe? Facts and controversies. Clin. Dermatol. 28: 67-72.
http://dx.doi.org/10.1016/j.clindermatol.2009.03.001
PMid:20082954
Ockenfels HM, Nussbaum G, Schultewolter T, Mertins K, et al. (1995). Tyrosine phosphorylation in psoriatic T cells is modulated by drugs that induce or improve psoriasis. Dermatology 191: 217-225.
http://dx.doi.org/10.1159/000246549
PMid:8534940
Ozawa A, Sugai J, Ohkido M, Ohtsuki M, et al. (1999). Cyclosporin in psoriasis: continuous monotherapy versus intermittent long-term therapy. Eur. J. Dermatol. 9: 218-223.
PMid:10210789
Prinz JC, Gross B, Vollmer S, Trommler P, et al. (1994). T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro via secreted products. Eur. J. Immunol. 24: 593-598.
http://dx.doi.org/10.1002/eji.1830240315
PMid:8125129
Rivera R and Murre C (2001). The regulation and function of the Id proteins in lymphocyte development. Oncogene 20: 8308-8316.
http://dx.doi.org/10.1038/sj.onc.1205091
PMid:11840323
Rocha-Pereira P, Santos-Silva A, Rebelo I, Figneiredo A, et al. (2004). Erythrocyte damage in mild and severe psoriasis. Br. J. Dermatol. 150: 232-244.
http://dx.doi.org/10.1111/j.1365-2133.2004.05801.x
PMid:14996093
Ronpirin C and Tencomnao T (2010). Psoriasis: A review of the role of serotonergic system. Afr. J. Biotechnol. 9: 1528- 1534.
Sakurai D, Yamaguchi A, Tsuchiya N, Yamamoto K, et al. (2001). Expression of ID family genes in the synovia from patients with rheumatoid arthritis. Biochem. Biophys. Res. Commun. 284: 436-442.
http://dx.doi.org/10.1006/bbrc.2001.4974
PMid:11394898
Schön MP and Boehncke WH (2005). Psoriasis. N. Engl. J. Med. 352: 1899-1912.
http://dx.doi.org/10.1056/NEJMra041320
PMid:15872205
Suh HC, Leeanansaksiri W, Ji M, Klarmann KD, et al. (2008). Id1 immortalizes hematopoietic progenitors in vitro and promotes a myeloproliferative disease in vivo. Oncogene 27: 5612-5623.
http://dx.doi.org/10.1038/onc.2008.175
PMid:18542061 PMCid:3073486
Szabo SK, Hammerberg C, Yoshida Y, Bata-Csorgo Z, et al. (1998). Identification and quantitation of interferon-gamma producing T cells in psoriatic lesions: localization to both CD4+ and CD8+ subsets. J. Invest. Dermatol. 111: 1072- 1078.
http://dx.doi.org/10.1046/j.1523-1747.1998.00419.x
PMid:9856819
Tam WF, Gu TL, Chen J, Lee BH, et al. (2008). Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells. Blood 112: 1981-1992.
http://dx.doi.org/10.1182/blood-2007-07-103010
PMid:18559972 PMCid:2518899
Vallat VP, Gilleaudeau P, Battat L, Wolfe J, et al. (1994). PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy. J. Exp. Med. 180: 283-296.
http://dx.doi.org/10.1084/jem.180.1.283
PMid:7516410
Vollmer S, Menssen A, Trommler P, Schendel D, et al. (1994). T lymphocytes derived from skin lesions of patients with psoriasis vulgaris express a novel cytokine pattern that is distinct from that of T helper type 1 and T helper type 2 cells. Eur. J. Immunol. 24: 2377-2382.
http://dx.doi.org/10.1002/eji.1830241018
PMid:7925564
Wong YC, Wang X and Ling MT (2004). Id-1 expression and cell survival. Apoptosis 9: 279-289.
http://dx.doi.org/10.1023/B:APPT.0000025804.25396.79
PMid:15258459
Yang Y, Liou HC and Sun XH (2006). Id1 potentiates NF-kappaB activation upon T cell receptor signaling. J. Biol. Chem. 281: 34989-34996.
http://dx.doi.org/10.1074/jbc.M608078200
PMid:17012234